MPH Health Care AG's Strong Performance Despite Challenges

First Berlin Equity Research GmbH recently released an update on MPH Health Care AG, confirming a BUY recommendation with a target price of €37. This follows the release of preliminary 2025 results. While a one-time write-down due to the insolvency of CR Energy has impacted MPH's results, M1 Kliniken AG, a subsidiary, showcased robust growth.

M1 Kliniken AG, specializing in lifestyle and beauty, achieved a 29% increase in EBIT, reaching €35 million. Its beauty segment sales exceeded €100 million for the first time, highlighting strong market demand. The prospects for sustained growth remain positive, further bolstered by M1's divestment of Haemato. This suggests a promising outlook for MPH's future financial performance.